FDA Advisory Panel Rejects Peptide Restriction Loosening, Hims & Hers Shares Drop
Shares of Hims & Hers Health (HIMS) fell over 11% on Friday after an FDA advisory panel rejected the first vote to loosen restrictions on a group of popular peptides. The decision signals regulatory resistance toward making these substances more accessible without stricter oversight. The rejection is significant for companies like Hims & Hers, which have been pushing for broader availability of certain peptides used in wellness and anti-aging treatments. A negative advisory panel recommendation often influences the FDA's final ruling, potentially delaying or blocking market access to such products. Investors reacted swiftly as the outcome raised concerns about regulatory hurdles that could impact revenue growth from these high-demand offerings.
Tickers: $HIMS
Topics: FDA advisory panel Hims & Hers Health peptides regulation